TY - JOUR
T1 - Basic Science and Pathogenesis
AU - Danielski, Lucineia
AU - Medeiros, Eduarda Behenck
AU - Zabot, Gabriel Casagrande
AU - Vargas, Adrielly
AU - Fenilli, Gabriela Piovesan
AU - De Jesus, Laura Ceolin
AU - Silveira, Gustavo De Bem
AU - Giridharan, Vijayasree V.
AU - Barichello, Tatiana
AU - Budni, Josiane
N1 - Publisher Copyright:
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - BACKGROUND: The increasing prevalence of neurodegenerative diseases, particularly among women post-menopause, is linked to the decline in 17 β estradiol (E2). Vitamin D deficiency, common in older individuals, exacerbates this risk due to its anti-inflammatory and neuroprotective properties. Hypovitaminosis D is associated with age-related conditions, including cognitive decline. Donepezil, an acetylcholinesterase inhibitor used for Alzheimer's dementia, targets cholinergic dysfunction in normal aging and prodromal states of this disease, suggesting a potential intervention for early disease modification. METHOD: Adult female Wistar rats aged 60 or 120 days were used, submitted to ovariectomy (OVX) for 1, 4, or 8 months, supplemented with vit D, at doses of 42 and 420 IU/kg, or water or combined with DONE (1 mg/kg) orally by gavage for 21 days. The open field test (OFT) and Y-maze test were performed. RESULT: Ovariectomized rats at 60 and 120 days of age exhibit deficits in short-term spatial reference memory, as evidenced by performance in the Y-maze task. In the OFT, 60-day-old rats subjected to OVX for four months displayed impairment, a trend also observed in rats of the same age undergoing OVX for eight months, both in the control and OVX groups. Notably, 120-day-old rats subjected to OVX for 4 and 8 months failed to learn, along with their respective control groups. However, the majority of interventions successfully reversed these memory impairments, with particular efficacy observed in treatments involving vitamin D at 42 IU/kg and the combination of vitamin D with DONE. CONCLUSION: Memory impairment occurs as a result of ovariectomy (OVX). This effect persists with aging, and vit D, either alone or in combination with DONE, emerges as a significant alternative for reversing or mitigating this cognitive decline.
AB - BACKGROUND: The increasing prevalence of neurodegenerative diseases, particularly among women post-menopause, is linked to the decline in 17 β estradiol (E2). Vitamin D deficiency, common in older individuals, exacerbates this risk due to its anti-inflammatory and neuroprotective properties. Hypovitaminosis D is associated with age-related conditions, including cognitive decline. Donepezil, an acetylcholinesterase inhibitor used for Alzheimer's dementia, targets cholinergic dysfunction in normal aging and prodromal states of this disease, suggesting a potential intervention for early disease modification. METHOD: Adult female Wistar rats aged 60 or 120 days were used, submitted to ovariectomy (OVX) for 1, 4, or 8 months, supplemented with vit D, at doses of 42 and 420 IU/kg, or water or combined with DONE (1 mg/kg) orally by gavage for 21 days. The open field test (OFT) and Y-maze test were performed. RESULT: Ovariectomized rats at 60 and 120 days of age exhibit deficits in short-term spatial reference memory, as evidenced by performance in the Y-maze task. In the OFT, 60-day-old rats subjected to OVX for four months displayed impairment, a trend also observed in rats of the same age undergoing OVX for eight months, both in the control and OVX groups. Notably, 120-day-old rats subjected to OVX for 4 and 8 months failed to learn, along with their respective control groups. However, the majority of interventions successfully reversed these memory impairments, with particular efficacy observed in treatments involving vitamin D at 42 IU/kg and the combination of vitamin D with DONE. CONCLUSION: Memory impairment occurs as a result of ovariectomy (OVX). This effect persists with aging, and vit D, either alone or in combination with DONE, emerges as a significant alternative for reversing or mitigating this cognitive decline.
UR - http://www.scopus.com/inward/record.url?scp=85214485120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85214485120&partnerID=8YFLogxK
U2 - 10.1002/alz.091739
DO - 10.1002/alz.091739
M3 - Article
C2 - 39750799
AN - SCOPUS:85214485120
SN - 1552-5260
VL - 20
SP - e091739
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -